[{"text": "LIVE The latest news and updates on Trump's tariffs Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia Clinical Trials Arena \u00b7 Shutterstock / Poetra.RH Joshua Silverwood Wed, Jan 8, 2025, 6:16 PM 2 min read In This Article: BCAX Indiana clinical-stage biopharmaceutical company, MBX Biosciences, has announced positive topline data from a Phase I trial of its glucagon-like peptide-1 receptor agonist (GLP-1RA) aimed at treating endocrine and metabolic disorders including post-bariatric hypoglycaemia (PBH). The randomised, double-blind, placebo-controlled study (NCT06036784) enrolled healthy volunteers across two cohorts, a single ascending arm (SAD) group and multiple ascending dose (MAD) arm. Both arms met the primary endpoints of overall safety and tolerability, with no adverse events observed. In the MAD cohort, MBX 1416 median half-life was approximately 90 hours, which the company says would support weekly dosing of the drug. Now, the company says it is looking to parse its success into a Phase II study set to start in the second half of this year. GLP-1RAs are typically more at home in the diabetes and weight loss spaces, but in recent years, the treatment has been trialled in several other indications . PBH is typically a complication of bariatric surgery that can result in low blood sugar levels. Kent Hawryluk, president and chief executive officer of MBX Biosciences, said: \u201cWe are encouraged by the positive topline Phase I results in healthy volunteers that showed MBX 1416 was generally well-tolerated with a favourable safety profile and a promising pharmacokinetic profile supportive of once-weekly dosing. \u201cWe also observed an apparent increase in GLP-1 peak during the first hour after a mixed meal tolerance test, which is an encouraging signal that we believe may translate into a therapeutic benefit in patients with PBH. Based on these results, we intend to initiate a Phase II study in patients with PBH in the second half of 2025 to further optimise dosing, pending alignment with the US Food and Drug Administration on our proposed study design.\u201d Additionally, results from the trial found the drug-drug interaction (DDI) portion of the trial, found MBX 1416 had little impact on rosuvastatin exposure, a commonly prescribed statin for patients living with post-bariatric hypoglycaemia. Elsewhere in the GLP1-RA space, New York obesity healthcare firm, Metsera has unveiled positive topline results from its Phase IIa trial of its GLP-1RA, MET-097i. Meanwhile, Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations. \"Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia\" was originally created and published by Clinical Trials Arena , a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BCAX", "date": "2025-01-08T18:16:27", "sentiment": {"score": 0.9022689675912261, "confidence": 0.9120318293571472, "probabilities": {"positive": 0.9120318293571472, "negative": 0.009762861765921116, "neutral": 0.07820530235767365}}, "embedding": [-0.01902642846107483, -0.051372136920690536, 0.008646104484796524, 0.022053103893995285, -0.10933665931224823, -0.06345996260643005, -0.0323987640440464, 0.18542775511741638, 0.007082177326083183, -0.06167278438806534, -0.14977221190929413, 0.09040984511375427, 0.004198987036943436, -0.0025542317889630795, 0.0632651150226593, -0.03150452300906181, 0.1950669288635254, -0.10881979018449783, -0.05390366166830063, 0.14975935220718384, 0.12405093759298325, -0.05913032591342926, 0.09210173785686493, 0.17149107158184052, -0.08229561150074005, -0.02228534035384655, -0.07067804038524628, -0.05557651072740555, -0.07650204002857208, -0.006803830619901419, 0.054731711745262146, 0.10439224541187286, 0.09074866771697998, 0.027983102947473526, -0.023888638243079185, 0.06752829253673553, -0.05335593596100807, 0.04842508211731911, -0.19541043043136597, -0.06971508264541626, 0.024255160242319107, -0.09498672187328339, -0.09304039925336838, 0.06534025073051453, -0.023926544934511185, -0.20111067593097687, -0.020115114748477936, 0.07731109857559204, -0.047222428023815155, 0.16548815369606018, -0.11413112282752991, -0.126256063580513, 0.048966385424137115, 0.06197430565953255, 0.04781404882669449, 0.009811321273446083, -0.10749053955078125, -0.015818540006875992, 0.017556896433234215, -0.04251837730407715, -0.133711040019989, -0.0055456701666116714, -0.06376145035028458, -0.02689339965581894, 0.13021345436573029, 0.00014494778588414192, 0.029526179656386375, -0.15828311443328857, 0.04057929292321205, -0.037377070635557175, 0.03689010813832283, -0.10904020816087723, -0.0107578681781888, 0.01493512187153101, 0.007029201369732618, 0.054987967014312744, 0.0008711726404726505, 0.07406099885702133, 0.04637179896235466, -0.07151618599891663, 0.04672446846961975, 0.06519628316164017, 0.0497359074652195, 0.12654606997966766, -0.03886866196990013, 0.005945011042058468, -0.050878122448921204, 0.16482490301132202, -0.062357097864151, -0.10942573845386505, 0.16529563069343567, 0.06694190949201584, -0.022200144827365875, 0.06223924458026886, 0.035876497626304626, -0.0575677752494812, -0.10336429625749588, 0.0003199954517185688, 0.09813261777162552, -0.0033842679113149643, 0.026754125952720642, 0.0463097020983696, -0.037624649703502655, 0.029673105105757713, -0.07256083190441132, -0.07507337629795074, 0.07132163643836975, -0.009947522543370724, 0.03202572092413902, -0.022548450157046318, 0.04572117328643799, 0.053797997534275055, 0.09579314291477203, 0.12446755915880203, -0.06736990064382553, 0.17159661650657654, -0.00406695157289505, 0.08047562837600708, 0.19744065403938293, 0.006084824912250042, 0.013377000577747822, -0.04385704547166824, 0.08157660067081451, -0.1345432698726654, 0.08825695514678955, 0.12150286138057709, -0.02147926762700081, 1.370284344202698e-32, 0.0650021955370903, -0.15589003264904022, 0.09285351634025574, -0.028154810890555382, -0.07171998172998428, -0.030341604724526405, -0.05413544178009033, -0.0837775319814682, 0.04409242421388626, 0.027828246355056763, -0.0207768976688385, -0.08048620820045471, 0.013651025481522083, 0.16637039184570312, -0.1214873343706131, -0.04677926003932953, -0.03610687702894211, 0.014112270437180996, 0.04662291333079338, 0.09271317720413208, -0.006230813916772604, -0.051266178488731384, 0.06082133948802948, -0.02414867840707302, -0.05318692326545715, 0.15038910508155823, -0.033787861466407776, 0.07797877490520477, -0.02460453286767006, 0.046460215002298355, -0.051377490162849426, -0.005391361191868782, 0.0073848506435751915, -0.07308509200811386, -0.16656199097633362, -0.11286106705665588, 0.009405497461557388, -0.07702336460351944, -0.027311697602272034, 0.05371519550681114, -0.05039612948894501, 0.08540140092372894, 0.008302992209792137, -0.17155835032463074, 0.15057975053787231, -0.01737021468579769, -0.09033746272325516, -0.033821381628513336, -0.053097277879714966, 0.08006079494953156, -0.013333669863641262, -0.01937945932149887, 0.0464031882584095, -0.03871520236134529, -0.09849684685468674, 0.056191302835941315, -0.053283482789993286, -0.08148781955242157, 0.08713166415691376, 0.15906421840190887, 0.07460661232471466, 0.12567797303199768, 0.005229603499174118, -0.017509257420897484, -0.03133796900510788, 0.15469497442245483, -0.04828343540430069, -0.13715335726737976, -0.20695218443870544, 0.05603579431772232, 0.00941508635878563, -0.06756976991891861, 0.1662992388010025, 0.02084558829665184, 0.07402981072664261, -0.14091746509075165, 0.07687819004058838, 0.12387880682945251, 0.012596295215189457, -0.09334675967693329, 0.10317087918519974, -0.050707511603832245, -0.042968280613422394, 0.12702766060829163, -0.059757184237241745, 0.022349189966917038, -0.008032364770770073, -0.1532122939825058, -0.16379967331886292, 0.0055984556674957275, -0.03877370432019234, -0.01696183532476425, -0.02492767572402954, 0.10983459651470184, -0.03708450868725777, -1.324711162905287e-32, 0.017271287739276886, -0.011294976808130741, 0.013425447046756744, -0.10007846355438232, -0.0032670898362994194, 0.0423196405172348, 0.13276726007461548, -0.10340166091918945, 0.18206757307052612, -0.08786548674106598, 0.10156060755252838, 0.07298798859119415, -0.09060847759246826, 0.005859609227627516, -0.05295366793870926, 0.04810585454106331, -0.0020817220211029053, -0.06315024197101593, -0.15008024871349335, 0.029486797749996185, 0.13246440887451172, 0.08550108969211578, -0.10775773227214813, -0.08476297557353973, 0.07729140669107437, 0.009027638472616673, 0.13238956034183502, 0.2459525316953659, 0.07461683452129364, -0.14727851748466492, -0.05902768671512604, 0.08642157912254333, -0.18559682369232178, -0.15901467204093933, -0.02908272109925747, -0.02492871694266796, -0.06860445439815521, -0.030629854649305344, -0.0549163781106472, -0.05695795267820358, 0.04318932816386223, 0.062516950070858, 0.016275784000754356, -0.07950372993946075, 0.07259753346443176, 0.0053707389160990715, 0.05666903033852577, -0.09377244114875793, 0.0557560957968235, -0.03470800071954727, -0.05859033763408661, 0.049361877143383026, 0.05281782150268555, 0.05582887679338455, 0.07240408658981323, -0.09173464775085449, 0.03344321995973587, -0.07952359318733215, -0.06669759005308151, -0.051605284214019775, -0.05841744318604469, 0.06893070042133331, 0.03275545686483383, 0.039884164929389954, 0.11772632598876953, 0.11172996461391449, 0.12514932453632355, -0.11952126026153564, 0.13319486379623413, 0.05122892186045647, -0.04309631139039993, -0.09732569754123688, 0.06421423703432083, -0.09182609617710114, 0.05293367803096771, 0.14897900819778442, -0.09385530650615692, -0.08378100395202637, -0.07716740667819977, -0.10074082016944885, -0.07684189081192017, -0.11354202032089233, -0.06615226715803146, -0.019780423492193222, 0.055260635912418365, 0.01800420694053173, -0.04389259219169617, -0.03961439058184624, 0.12918256223201752, 0.10118377953767776, -0.14448922872543335, -0.09133251011371613, -0.055961139500141144, 0.032300788909196854, 0.01925157569348812, -1.0075650891394616e-07, 0.10545226186513901, -0.11712755262851715, -0.03539133444428444, 0.016193680465221405, -0.01120974775403738, -0.012276792898774147, -0.048825014382600784, -0.03077618032693863, -0.05224224179983139, 0.1030946671962738, 0.10300925374031067, 0.1508605182170868, -0.01282460056245327, -0.12498381733894348, -0.15555249154567719, 0.0027537718415260315, -0.021997742354869843, 0.003338283160701394, -0.03726878762245178, -0.007884809747338295, -0.13519060611724854, -0.0795603096485138, 0.05177086591720581, -0.07346956431865692, 0.10478813201189041, -0.03879283741116524, 0.07153311371803284, 0.11356285959482193, 0.05069440230727196, -0.06649588793516159, 0.007143802009522915, 0.01584899052977562, 0.06791015714406967, 0.08971350640058517, 0.050445638597011566, -0.13933871686458588, -0.03769434988498688, 0.19926846027374268, 0.0869465172290802, 0.01459692232310772, -0.040214456617832184, -0.07785797119140625, 0.013002641499042511, 0.030152853578329086, 0.09231366962194443, -0.015545995905995369, -0.15347982943058014, 0.043491531163454056, 0.04923247545957565, -0.05278032273054123, -0.04964973032474518, 0.03621955215930939, -0.07904216647148132, 0.014973459765315056, -0.012778172269463539, 0.162591353058815, -0.09868316352367401, -0.08562789857387543, 0.04287051409482956, -0.08641363680362701, 0.10325787216424942, -0.12129510939121246, -0.07241795212030411, -0.07536792010068893], "changes": {"1wk": -15.278688024301998}}, {"text": "LIVE The latest news and updates on Trump's tariffs Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium Bicara Therapeutics Inc. Mon, Jan 27, 2025, 4:00 PM 6 min read In This Article: BCAX Bicara Therapeutics Inc. BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC). The results were presented in a poster session during the 2025 ASCO Gastrointestinal (GI) Cancers Symposium on Saturday, January 25, 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2), and is being evaluated in multiple solid tumor types. \u201cWe are encouraged by the preliminary data in SCAC, which demonstrate enhanced efficacy of the combination of ficerafusp alfa and pembrolizumab in a high-need patient population,\u201d said David Raben, MD, Chief Medical Officer of Bicara Therapeutics. \u201cThe addition of ficerafusp alfa shows the potential to improve efficacy compared to historical data with pembrolizumab monotherapy in SCAC, with increased overall response rate, disease control rate, and 12-month progression-free survival, indicative of improved speed, depth, and durability of response. Importantly, responses were observed even in patients with liver metastases, which is a significant outcome in this setting. These data provide additional insights into the complimentary mechanisms of ficerafusp alfa and pembrolizumab, and support further development in squamous cell carcinomas, including first-line recurrent/metastatic head and neck squamous cell carcinoma.\u201d \u201cThese early data with ficerafusp alfa and pembrolizumab suggest that ficerafusp alfa could play an important role in the future treatment of SCAC, underscoring the need for further investigation to assess the combination's potential in improving outcomes for patients,\u201d said Van K. Morris, MD, Associate Professor of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center. Presentation Highlights: As of the data cut-off date of December 5, 2024, the single-arm, multicenter dose expansion cohort from an ongoing Phase 1/1b trial evaluated ficerafusp alfa in combination with pembrolizumab in 28 patients with immune checkpoint inhibitor-naive SCAC that was locally advanced/unresectable or metastatic, and who had received 1-2 prior lines of chemotherapy. The confirmed overall response rate was 25.0% (7/28 patients), irrespective of PD-L1 CPS score, including 6 partial responses (PR) and 1 complete response. In addition to the confirmed responses, there was 1 patient pending a confirmed PR. Median progression-free survival (PFS) was 2.9 months and the PFS rate at 12 months was 40.7% (27 evaluable patients). Tolerable safety profile with the most common treatment-related adverse events of any grade including, acneiform dermatitis (16/28 patients; 57.1%), epistaxis (14/28 patients; 50.0%), and pruritus (13/28 patients; 46.4%). Story Continues Presentation Details: Title: Preliminary Phase 1/1b dose expansion results of the bifunctional EGFR/TGF\u03b2 inhibitor ficerafusp alfa (BCA101) with pembrolizumab in patients with squamous cell carcinoma of the anal canal Presenter: Van K. Morris, MD, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center The poster presentation is available on the Bicara website under the Presentations & Publications section. About Squamous Cancer of the Anal Canal Squamous cancer of the anal canal (SCAC) is the most common type of anal canal cancer, with an incidence in the United States. SCAC is typically associated with prior Human Papillomavirus (HPV) infection. Treatment is most commonly chemoradiation for patients with localized disease at diagnosis. About Ficerafusp Alfa Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-b signaling within the tumor microenvironment. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-\u03b2 signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential and clinical benefits of ficerafusp alfa, the potential efficacy and safety of ficerafusp alfa in combination with pembrolizumab in SCAC, and plans for the clinical development of ficerafusp alfa in combination with pembrolizumab. The words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cpredict,\u201d \u201cfuture,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. These and other risks and uncertainties are described in greater detail in the section entitled \u201cRisk Factors\u201d in Bicara\u2019s most recent Quarterly Report on Form 10-Q for the period ended September 30, 2024, and filed with the Securities and Exchange Commission (SEC), as well as any subsequent filings that Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara\u2019s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contacts Investors Rachel Frank IR@bicara.com Media Dan Budwick 1AB dan@1abmedia.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BCAX", "date": "2025-01-27T16:00:00", "sentiment": {"score": 0.8844136851839721, "confidence": 0.8920908570289612, "probabilities": {"positive": 0.8920908570289612, "negative": 0.007677171844989061, "neutral": 0.10023195296525955}}, "embedding": [0.0539766401052475, -0.20722763240337372, -0.09959129989147186, -0.14510975778102875, -0.16759438812732697, -0.10275226086378098, -0.05583607405424118, 0.18662810325622559, 0.1523967832326889, 0.05487126484513283, -0.05843115597963333, 0.04827495664358139, -0.07852976024150848, 0.0367199182510376, -0.06072895973920822, 0.14677342772483826, 0.03288315609097481, -0.012687988579273224, -0.07969225943088531, 0.028329603374004364, -0.017180711030960083, -0.056805334985256195, 0.11523571610450745, 0.08123810589313507, -0.050474490970373154, -0.08074331283569336, -0.04422392696142197, 0.017695223912596703, -0.23380795121192932, 0.014361167326569557, 0.08362989127635956, 0.048788268119096756, 0.03451482206583023, -0.06804826110601425, -0.020863018929958344, -0.11771908402442932, -0.09815414249897003, 0.07660409808158875, -0.059279367327690125, -0.12127183377742767, -0.06764477491378784, -0.042771607637405396, -0.06439250707626343, -0.040265168994665146, 0.08472695201635361, -0.30896472930908203, -0.11966203898191452, 0.028274377807974815, 0.032059576362371445, 0.2952650785446167, -0.05631086602807045, -0.0025336993858218193, -0.08337065577507019, 0.27128076553344727, 0.016888299956917763, -0.06835359334945679, -0.12142504751682281, 0.046272654086351395, 0.042455703020095825, 0.11645416915416718, -0.05989997833967209, -0.16756226122379303, 0.05120307207107544, 0.06762798130512238, 0.02806972712278366, 0.06175850331783295, 0.03210265189409256, -0.14208272099494934, -0.17595091462135315, 0.04701618477702141, -0.06826357543468475, -0.10820019245147705, 0.04966112971305847, 0.10923470556735992, 0.07470037043094635, -0.06787119805812836, 0.12495528161525726, 0.20223432779312134, 0.06452915817499161, 0.03448402136564255, -0.024639660492539406, 0.1305914670228958, -0.03342030569911003, 0.00490979477763176, -0.1076933741569519, 0.03599812090396881, -0.008674588054418564, 0.07827955484390259, -0.03531978279352188, -0.001030903309583664, 0.18134838342666626, 0.1286090761423111, -0.0008776995819061995, -0.013662287965416908, 0.1265316903591156, -0.025497926399111748, -0.2006223201751709, -0.035551708191633224, 0.12367912381887436, -0.0607416033744812, -0.06709446758031845, 0.003402547910809517, -0.01563306897878647, -0.19617149233818054, -0.034852005541324615, -0.012607507407665253, -0.03549085929989815, 0.016307950019836426, -0.02825930342078209, -0.059393689036369324, 0.07053554058074951, -0.014858759008347988, 0.1515396237373352, 0.03080619126558304, -0.03092082589864731, 0.16691574454307556, -0.0791039764881134, -0.025930192321538925, 0.18487492203712463, 0.057901132851839066, -0.004069195128977299, 0.064191073179245, 0.005053815431892872, 0.0572841502726078, 0.03301282227039337, 0.11187180876731873, -0.03747241199016571, 1.0987929036207517e-32, 0.00014480482786893845, -0.07481461763381958, 0.017683904618024826, 0.12600375711917877, 0.005543502047657967, -0.06142556667327881, 0.049903504550457, -0.07603612542152405, -0.2138105034828186, 0.04442405328154564, -0.012507353909313679, 0.09995725750923157, 0.04445541650056839, 0.003543769707903266, -0.03506774827837944, 0.015888893976807594, -0.03474695235490799, 0.035793691873550415, -0.04102947190403938, -0.051883962005376816, 0.039617251604795456, 0.03844466805458069, -0.04660428687930107, -0.12083160877227783, 0.045068930834531784, 0.08258575946092606, -0.05515298992395401, 0.10001976042985916, 0.03408893942832947, 0.02068132348358631, -0.13949164748191833, 0.07827473431825638, -0.009567790664732456, -0.05835986137390137, -0.07411240041255951, -0.13351106643676758, -0.05294613540172577, -0.06674862653017044, -0.029820237308740616, 0.10993558168411255, 0.14989930391311646, -0.003593115136027336, -0.13231021165847778, 0.011912654154002666, 0.09834286570549011, -0.17411890625953674, -0.11272032558917999, 0.125228151679039, 0.07098211348056793, 0.09363880753517151, 0.05058782547712326, 0.0020449792500585318, -0.007277003023773432, 0.10740325599908829, -0.042917296290397644, 0.08581237494945526, -0.19428755342960358, 0.050032805651426315, 0.12109460681676865, 0.04045070707798004, -0.09687681496143341, 0.012546604499220848, -0.0015398920513689518, 0.02890142612159252, -0.06297963857650757, 0.050803013145923615, -0.038286808878183365, 0.018560167402029037, -0.049813900142908096, -0.020999830216169357, -0.08551007509231567, 0.02131148800253868, 0.11189951747655869, 0.1282283365726471, 0.08295157551765442, -0.14010265469551086, 0.11670089513063431, 0.18807190656661987, -0.06244067847728729, 0.12668417394161224, -0.15642890334129333, -0.05530916899442673, -0.05074591934680939, 0.0732395350933075, -0.0014849118888378143, -0.11029185354709625, -0.032610610127449036, -0.11722753196954727, -0.130279541015625, -0.04001137241721153, 0.12529540061950684, 0.012243583798408508, -0.13548694550991058, 0.19690309464931488, 0.08812986314296722, -1.3521170790107395e-32, 0.015311025083065033, -0.04537288472056389, 0.029420454055070877, 0.05589353293180466, -0.03136792778968811, 0.09613142907619476, 0.062436968088150024, -0.1448148638010025, 0.059761740267276764, -0.04387938231229782, 0.07386590540409088, 0.2016150951385498, 0.015701059252023697, -0.21090152859687805, 0.03840313479304314, 0.002344774082303047, 0.05217951908707619, -0.03750217705965042, -0.20620107650756836, 0.041190698742866516, -0.06500062346458435, 0.17756494879722595, 0.04063586890697479, -0.046804800629615784, -0.13951405882835388, 0.048850178718566895, 0.1906924545764923, 0.04340880736708641, 0.03350498154759407, 0.03277282416820526, 0.015285600908100605, 0.1054985523223877, -0.2707928717136383, -0.023927951231598854, -0.03870058432221413, -0.07567232847213745, 0.020879678428173065, -0.2361929565668106, -0.03700026869773865, -0.032080285251140594, 0.016516460105776787, 0.08599181473255157, -0.13020463287830353, -0.07758922129869461, -0.09313588589429855, 0.08820408582687378, 0.1536562740802765, -0.03198482468724251, 0.06104457378387451, -0.0012737903743982315, 0.041821129620075226, 0.1748589277267456, -0.009029984474182129, -0.0057581765577197075, 0.05407942831516266, 0.036365658044815063, 0.060483574867248535, -0.1025439202785492, -0.05367198586463928, 0.0787954106926918, -0.02978527918457985, 0.07673343271017075, 0.17648881673812866, -0.044400881975889206, 0.180364191532135, 0.043476447463035583, 0.011000096797943115, -0.14535416662693024, -0.0219181589782238, 0.0548212043941021, -0.06533179432153702, -0.02763311192393303, -0.045998916029930115, -0.020815495401620865, 0.04701187461614609, 0.32829850912094116, 0.03387220948934555, -0.18669410049915314, -0.08698660880327225, 0.045225195586681366, -0.018739884719252586, 0.043157756328582764, -0.00817757286131382, -0.0058953408151865005, 0.12096776068210602, -0.010453011840581894, -0.16424305737018585, -0.015383144840598106, -0.005787067115306854, 0.13152164220809937, 0.015154709108173847, -0.18225671350955963, -0.04435383528470993, -0.010805036872625351, -0.061713043600320816, -1.0011414275368224e-07, -0.01496151927858591, 0.06827760487794876, -0.06862963736057281, -0.04366439953446388, 0.019828688353300095, 0.02255004271864891, -0.09933160245418549, 0.006816477980464697, -0.17820829153060913, 0.10272076725959778, 0.014418390579521656, 0.14062339067459106, -0.0961557924747467, 0.03136599808931351, -0.04145750775933266, 0.031383465975522995, 0.005984158255159855, -0.11499054729938507, -0.0483422577381134, -0.034728504717350006, -0.15149378776550293, -0.07475602626800537, 0.04251767322421074, -0.03506553918123245, 0.03612477332353592, -0.09924711287021637, -0.05159715935587883, 0.20091669261455536, 0.024274606257677078, -0.009110266342759132, -0.05176559090614319, -0.07017479091882706, -0.04891993850469589, 0.06038676202297211, -0.09993475675582886, -0.0832904726266861, 0.05329013615846634, 0.05682509392499924, -0.08054590225219727, 0.2009449303150177, 0.18265557289123535, -0.11101649701595306, -0.026910942047834396, -0.09672881662845612, -0.14888188242912292, 0.052924931049346924, -0.07822714000940323, 0.02993379905819893, -0.057190850377082825, 0.07170696556568146, 0.016449857503175735, -0.029823485761880875, -0.01495564728975296, -0.06795181334018707, 0.03700367361307144, 0.0909760445356369, -0.03896879404783249, -0.016643088310956955, 0.20153352618217468, 0.02044183760881424, -0.1176384910941124, -0.0028787371702492237, 0.05563785135746002, -0.041050687432289124], "changes": {"1wk": 8.326182822237557}}, {"text": "LIVE The latest news and updates on Trump's tariffs Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference Bicara Therapeutics Inc. Tue, Nov 12, 2024, 12:01 AM 1 min read In This Article: BCAX Bicara Therapeutics Inc. BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET. A live webcast of the presentation will be available on the Events and Presentations section of Bicara\u2019s website at www.bicara.com . An archived replay of the webcast will be available for approximately 90 days following the presentation. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-\u03b2 signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X. Contacts Investors Rachel Frank IR@bicara.com Media Dan Budwick 1AB dan@1abmedia.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BCAX", "date": "2024-11-12T00:01:00", "sentiment": {"score": 0.11592786107212305, "confidence": 0.12446177750825882, "probabilities": {"positive": 0.12446177750825882, "negative": 0.008533916436135769, "neutral": 0.8670042753219604}}, "embedding": [-0.053193069994449615, -0.029457347467541695, -0.08584713935852051, -0.13194923102855682, -0.09405981749296188, 0.007936885580420494, -0.07429713755846024, 0.19607630372047424, 0.07810220122337341, 0.022479763254523277, -0.08560658991336823, 0.022477012127637863, -0.06205005571246147, 0.01098896749317646, -0.03729080781340599, 0.27649909257888794, 0.04708993062376976, 0.04916238784790039, -0.028536485508084297, 0.09263566136360168, 0.050290558487176895, -0.005800580605864525, 0.012944101355969906, 0.14277039468288422, -0.11662724614143372, -0.04011361673474312, 0.0017094495706260204, -0.024928119033575058, -0.2442825883626938, -0.055792950093746185, 0.009255301207304, 0.140428364276886, 0.0969301089644432, -0.10091958940029144, -0.11815787851810455, -0.012192247435450554, -0.06512369960546494, -0.02909979410469532, -0.01872267574071884, -0.10227398574352264, -0.046180397272109985, -0.018039684742689133, -0.05008936673402786, -0.024411674588918686, 0.04024479165673256, -0.2569276988506317, -0.05322171375155449, 0.0664663165807724, 0.02250504307448864, 0.21965661644935608, -0.13915303349494934, -0.0659848004579544, -0.08106274902820587, 0.1769116371870041, -0.015498459339141846, -0.026095177978277206, -0.12977269291877747, 0.04708820581436157, 0.1259060502052307, -0.041055552661418915, 0.034220270812511444, -0.06542522460222244, 0.11736788600683212, 0.06931786239147186, 0.06514829397201538, -0.0071171545423567295, -0.06240022927522659, -0.06914154440164566, -0.11220244318246841, 0.02921801432967186, 0.03163941949605942, -0.11225911974906921, 0.06993662565946579, 0.07969003170728683, 0.0763220489025116, 0.03135605901479721, 0.1366083174943924, 0.1096370741724968, 0.10908406227827072, 0.04994479939341545, -0.04911435768008232, 0.13018281757831573, 0.08162938058376312, -0.043949827551841736, -0.03250274062156677, 0.05414986610412598, -0.03721213340759277, 0.053169071674346924, -0.02086891233921051, 0.04927355423569679, 0.09567124396562576, 0.10712254792451859, -0.011346696875989437, 0.05148029699921608, 0.05414644256234169, -0.09441623091697693, -0.10245275497436523, -0.0068980734795331955, 0.14843977987766266, -0.027110647410154343, 0.01229120697826147, 0.023479389026761055, 0.03345886245369911, -0.0895429477095604, -0.11973898112773895, -0.059726960957050323, 0.08038277924060822, 0.05593156814575195, 0.04532967507839203, -0.043233416974544525, -0.04351557418704033, -0.011699099093675613, 0.09338360279798508, -0.041617751121520996, -0.09822352975606918, 0.23827046155929565, -0.09490461647510529, -0.03146698698401451, 0.17650772631168365, 0.04816024377942085, 0.07489534467458725, 0.09172559529542923, -0.005616347771137953, -0.06525309383869171, 0.05069126933813095, 0.1033102348446846, -0.12226330488920212, 1.3143021604287558e-32, 0.05591548606753349, -0.04893924668431282, 0.09748195111751556, 0.10216539353132248, -0.005822114180773497, -0.08221596479415894, 0.03492738679051399, -0.12261010706424713, -0.1664980947971344, -0.07363912463188171, -0.06930609792470932, 0.1490469127893448, 0.06087648868560791, 0.06255517899990082, -0.06303717941045761, -0.12087203562259674, -0.026374582201242447, 0.022247208282351494, 0.12100246548652649, -0.06657446920871735, 0.0774526372551918, 0.0755009725689888, -0.09675833582878113, -0.031223228201270103, -0.013224381022155285, 0.15364062786102295, 0.04858049005270004, 0.06057596579194069, 0.06534762680530548, 0.07637252658605576, -0.20489539206027985, 0.10825870931148529, -0.07066688686609268, -0.17051371932029724, 0.010170361958444118, -0.1387633979320526, -0.108983114361763, -0.11706143617630005, -0.06632979959249496, -0.007653713691979647, 0.08101655542850494, -0.018320143222808838, -0.12052448838949203, 0.003918267320841551, 0.08559790998697281, -0.11709001660346985, -0.1418771594762802, 0.00783898588269949, 0.08241710066795349, 0.028295153751969337, 0.08019884675741196, -0.05306879058480263, -0.029813895002007484, 0.051408275961875916, -0.026668494567275047, 0.07014311105012894, -0.20333623886108398, -0.05243828147649765, 0.11486691981554031, 0.07751179486513138, -0.01796524040400982, 0.10765830427408218, 0.034845951944589615, -0.047476012259721756, -0.06676258891820908, -0.07019713521003723, -0.09815376251935959, -0.08582963049411774, -0.12124580889940262, -0.02110733650624752, 0.035507429391145706, 0.003549948101863265, 0.1584608405828476, 0.08275856077671051, 0.03295588493347168, -0.10349253565073013, 0.099734827876091, 0.11344199627637863, -0.07720763981342316, 0.06562905013561249, -0.03131523355841637, 0.047594353556632996, -0.0941012054681778, 0.013651704415678978, -0.026125529780983925, -0.12795670330524445, -0.04139212891459465, -0.10998386889696121, -0.20232722163200378, 0.014921783469617367, 0.07242143899202347, -0.053588900715112686, -0.10270480811595917, 0.15183673799037933, 0.039853520691394806, -1.4829083110181875e-32, 0.00048788770800456405, -0.09104420989751816, 0.0744602158665657, -0.008182121440768242, -0.02597140707075596, 0.06050879880785942, 0.0564512237906456, -0.14291499555110931, 0.09502312541007996, -0.051549531519412994, 0.004987395368516445, 0.05815385282039642, -0.03137378767132759, -0.07741378992795944, -0.06996215879917145, 0.025471394881606102, 0.0761982873082161, -0.0765758827328682, -0.21276599168777466, -0.04550846293568611, 0.008208231069147587, 0.19674360752105713, -0.07729395478963852, 0.03125765174627304, -0.10766830295324326, 0.03867010399699211, 0.11175799369812012, 0.0756542980670929, 0.09002881497144699, 0.0077603282406926155, -0.005913182161748409, 0.04955749958753586, -0.27783647179603577, 0.03220083564519882, -0.08207564800977707, -0.01090438012033701, 0.008212629705667496, -0.12837325036525726, 0.045280035585165024, -0.13951122760772705, 0.0717768594622612, -0.002985707251355052, -0.14002318680286407, 0.020895199850201607, 0.08105061203241348, 0.07099847495555878, 0.12233316153287888, 0.01995742693543434, 0.09435925632715225, 0.07111035287380219, -0.0013459328329190612, 0.08165823668241501, -0.028695357963442802, -0.06751006841659546, 0.02626902610063553, -0.007313832640647888, 0.06491326540708542, -0.11408568173646927, 0.035772837698459625, 0.00799047201871872, 0.01783495768904686, 0.041556887328624725, 0.11411160230636597, -0.047955747693777084, 0.09585608541965485, 0.10733725875616074, 0.07229578495025635, -0.03891816735267639, 0.08858053386211395, 0.01629006303846836, 0.019279589876532555, 0.05262758582830429, -0.06044793874025345, -0.01264650747179985, 0.05466986820101738, 0.1918133646249771, 0.01150722149759531, -0.1856929361820221, -0.09772327542304993, -0.01499340683221817, -0.027553314343094826, -0.0822446420788765, 0.0934830754995346, 0.02914426103234291, 0.08622466772794724, -0.012192880734801292, -0.03181358426809311, -0.06278029084205627, -0.03633248805999756, 0.02725236304104328, -0.0782783180475235, -0.15377964079380035, -0.07731787860393524, 0.03395959734916687, -0.0873047485947609, -1.0018695917324294e-07, 0.07416412979364395, -0.011715445667505264, -0.09581839293241501, -0.11405881494283676, -0.05169249325990677, -0.011879305355250835, -0.057710032910108566, 0.009478189051151276, -0.030694935470819473, 0.0743919312953949, -0.01235207263380289, 0.10049907118082047, -0.06729293614625931, -0.003830528352409601, 0.005995383020490408, 0.04606498032808304, 0.05241691693663597, -0.01728522963821888, -0.04495248943567276, -0.14199423789978027, -0.12064811587333679, -0.02270258218050003, 0.00908005703240633, 0.028563430532813072, 0.01943054422736168, -0.13505634665489197, -0.007834786549210548, 0.15872900187969208, 0.06424586474895477, -0.04759294539690018, -0.014383583329617977, 0.06667784601449966, 0.008166303858160973, 0.0014373777667060494, -0.04697082191705704, -0.13106507062911987, 0.04411008581519127, 0.08307696878910065, -0.021913951262831688, 0.13033340871334076, 0.0560527965426445, -0.023155195638537407, -0.01769406907260418, -0.07442261278629303, -0.13726268708705902, -0.04095856845378876, -0.00870045181363821, 0.05588715150952339, -0.011654762551188469, -0.018751302734017372, -0.02330051176249981, -0.06675709784030914, -0.014997596852481365, 0.02652895264327526, -0.02838134951889515, 0.17875142395496368, 0.008455020375549793, -0.0665740892291069, 0.17450089752674103, -0.05644954368472099, -0.0010021617636084557, -0.06764340400695801, 0.08499086648225784, 0.04586850106716156], "changes": {"1wk": -20.38573534260759, "1mo": -17.378682820350704}}, {"text": "LIVE The latest news and updates on Trump's tariffs Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Bicara Therapeutics Inc. Tue, Nov 12, 2024, 3:30 PM 9 min read In This Article: BCAX Bicara Therapeutics Inc. On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters\u2019 option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. \u201cThe third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-\u03b2 inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,\u201d said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics. \u201cWe are currently on track to achieve several anticipated milestones, most notably the upcoming initiation of FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa, for the treatment of recurrent/metastatic head and neck squamous cell carcinoma, following encouraging interim Phase 1/1b data and alignment with the FDA on the registrational trial design. Bolstered by our strong financial position with cash runway expected to fund operations into the first half of 2029, we are committed to bringing ficerafusp alfa to patients with head and neck squamous cell carcinoma and other solid tumors as quickly as possible.\u201d Pipeline Highlights Bicara is developing ficerafusp alfa, a first-in-class, dual-action bifunctional epidermal growth factor receptor (EGFR)/transforming growth factor beta (TGF-\u03b2) antibody for multiple different solid tumor cancer types. Planned Pivotal Phase 2/3 Clinical Trial in 1L R/M HNSCC The Company has aligned with the\u00a0U.S. Food and Drug Administration on the design of FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) and expects to initiate the trial late in the fourth quarter of 2024 or early in the first quarter of 2025. Ongoing Phase 1/1b Clinical Trial in 1L R/M HNSCC In an ongoing Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab has demonstrated clinically meaningful anti-tumor activity, with a 64% overall response rate, 18% complete response rate and median progression free survival of 9.8 months in frontline human papillomavirus (HPV)-negative R/M HNSCC, along with a favorable tolerability profile, as of the April 2024 data cut-off date (presented at the 3rd Hawaii Global Summit on Thoracic Malignancies in June 2024). Updated data from an ongoing Phase 1/1b trial is expected at a medical meeting in the first half of 2025. Story Continues Expansion into Other HNSCC Populations and Solid Tumor Types Data from a Phase 1b expansion cohort evaluating ficerafusp alfa in combination with pembrolizumab in second line (2L) or later squamous cancer of the anal canal is expected at a medical meeting in the first quarter of 2025. Updated data from a Phase 1b expansion cohort evaluating ficerafusp alfa monotherapy in 2L or later cutaneous squamous cell carcinoma is expected at a medical meeting in the first half of 2025. Business Highlights In September 2024, Bicara completed its initial public offering (IPO) of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, including full exercise of the underwriters\u2019 option to purchase additional shares, raising gross proceeds of approximately $362 million, before deducting underwriting discounts, commissions and other offering expenses. Shares began trading on the Nasdaq Global Market under the symbol \u201cBCAX.\u201d In conjunction with its IPO in September 2024, Bicara appointed its President and Chief Operating Officer, Ryan Cohlhepp, PharmD, as a Director to its Board of Directors. In August 2024, Bicara expanded its Board of Directors with the appointments of biopharma industry leaders Mike Powell, PhD, as Chairman of the Board, and Christopher Bowden, MD, as a Director. Third Quarter 2024 Financial Results Cash Position: As of September 30, 2024, Bicara had cash and cash equivalents of $520.8 million, compared to $230.4 million as of December 31, 2023. Based on its current operating and development plans, the Company expects that its existing cash and cash equivalents will fund operations into the first half of 2029. Research and Development Expenses: Research and development expenses were $15.9 million for the third quarter of 2024, compared to $6.9 million for the third quarter of 2023. The increase was primarily due to additional costs associated with the Company\u2019s ongoing clinical trials to advance ficerafusp alfa. General and Administrative Expenses: General and administrative expenses were $4.8 million for the third quarter of 2024, compared to $2.6 million for the third quarter of 2023. The increase in general and administrative expenses was primarily due to additional personnel costs and professional fees to prepare Bicara to operate as a public company. Net Loss: Net loss was $17.5 million for the third quarter of 2024, compared to $22.8 million for the third quarter of 2023. Net loss for the third quarter of 2023 included a $13.3 million non-cash expense that represents the change in fair value of Bicara\u2019s Series B preferred stock tranche rights liability. About Bicara Therapeutics Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara\u2019s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-\u03b2). Through this dual-targeting mechanism, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-\u03b2 signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, Bicara\u2019s expectations regarding plans for its current and future clinical trials, the anticipated timing of the initiation of FORTIFI-HN01, Bicara\u2019s pivotal Phase 2/3 clinical study, the anticipated timing of dosing patients and receiving data from Bicara\u2019s Phase 1/1b expansion cohorts evaluating ficerafusp alfa in combination with pembrolizumab; the expected therapeutic potential and clinical benefits of ficerafusp alfa, including potential efficacy and tolerability, and the timing and success of interactions with and approval of regulatory authority; the anticipated contribution of the members of Bicara\u2019s board of directors to its operations and progress; and financial projections and expectations regarding the time period in which our capital resources will be sufficient to fund our anticipated operations including our cash runway, use of capital, expenses and other financial results. The words \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cpredict,\u201d \u201cfuture,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar words or expressions, or the negative thereof, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including the conduct of research activities and the conduct of clinical trials; uncertainties as to the availability and timing of results and data from clinical trials; whether results from prior preclinical studies and clinical trials will be predictive of the results of subsequent preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; whether Bicara\u2019s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Bicara\u2019s filings with the Securities and Exchange Commission (SEC), including Bicara\u2019s upcoming Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and any subsequent filings Bicara makes with the SEC. In addition, any forward-looking statements represent Bicara\u2019s views only as of today and should not be relied upon as representing its views as of any subsequent date. Bicara explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Bicara intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company\u2019s Investor Relations website, in addition to following the Company\u2019s press releases, SEC filings, public conference calls, presentations, and webcasts. Contacts Investors Rachel Frank IR@bicara.com Media Dan Budwick 1AB dan@1abmedia.com BICARA THERAPEUTICS INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands except shares and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Operating expenses Research and development - related party $ 2,310 $ 2,271 $ 7,400 $ 6,511 Research and development 13,554 4,668 36,336 13,544 General and administrative 4,764 2,591 12,016 6,147 Total operating expenses 1 20,628 9,530 55,752 26,202 Loss from operations (20,628 ) (9,530 ) (55,752 ) (26,202 ) Other (expenses) income Interest income 3,147 13 8,715 13 Change in fair value of Series B preferred stock tranche rights liability \u2014 (13,328 ) \u2014 (13,356 ) Total other income (expense) 3,147 (13,315 ) 8,715 (13,343 ) Net loss before income taxes (17,481 ) (22,845 ) (47,037 ) (39,545 ) Income tax expense \u2013 \u2013 (1 ) \u2013 Net loss $ (17,481 ) $ (22,845 ) $ (47,038 ) $ (39,545 ) Net Loss per share, basic and diluted $ (1.60 ) $ (38.23 ) $ (11.27 ) $ (70.18 ) Weighted-average number common shares outstanding, basic and diluted 10,901,138 597,586 4,174,353 563,483 1 Expenses include the following non-cash stock-based compensation expense Research & Development $ 1,469 $ 398 $ 3,172 $ 924 General and administrative 562 121 1,044 210 Total stock-based compensation expense $ 2,031 $ 519 $ 4,216 $ 1,134 BICARA THEAPEUTICS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except shares and per share data) September 30, 2024 December 31, 2023 Assets (Unaudited) Current assets: Cash and cash equivalents $ 520,758 $ 230,440 Prepaid expenses and other assets 756 633 Total current assets 521,514 231,073 Property and equipment, net 130 202 Right of use asset \u2013 operating lease 414 613 Other assets 2,115 2,094 Total assets $ 524,173 $ 233,982 Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit) Current liabilities: Accounts payable $ 1,531 $ 2,142 Accounts payable \u2013 related party 431 1,044 Accrued expenses and other current liabilities 10,410 8,053 Accrued expenses and other current liabilities \u2013 related party 1,801 3,561 Operating lease liability \u2013 current portion 308 285 Total current liabilities 14,481 15,085 Operating lease liability \u2013 net of current portion 137 372 Other liabilities \u2014 17 Total liabilities 14,618 15,474 Total redeemable convertible preferred stock \u2014 367,277 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BCAX", "date": "2024-11-12T15:30:00", "sentiment": {"score": 0.9076075740158558, "confidence": 0.9173014760017395, "probabilities": {"positive": 0.9173014760017395, "negative": 0.009693901985883713, "neutral": 0.07300462573766708}}, "embedding": [-0.06923506408929825, -0.0655008852481842, -0.010814696550369263, -0.13547784090042114, -0.10110343992710114, -0.07357676327228546, -0.09280918538570404, 0.21545344591140747, 0.11573007702827454, 0.0790824443101883, -0.09489704668521881, -0.05874093621969223, -0.07064614444971085, -0.007658085785806179, -0.012043294496834278, 0.15004651248455048, 0.07010815292596817, 0.029181858524680138, -0.06987570226192474, 0.0946558490395546, -0.021564550697803497, -0.062126047909259796, 0.037505485117435455, 0.11260387301445007, -0.05907251313328743, -0.042480986565351486, -0.06329405307769775, -0.04357398673892021, -0.2657080888748169, -0.07062334567308426, 0.09607241302728653, 0.15914076566696167, 0.08843672275543213, -0.13208703696727753, -0.08672452718019485, 0.005529431626200676, -0.11257976293563843, 0.012533513829112053, -0.028710652142763138, -0.09974528104066849, -0.03959321975708008, -0.04705975949764252, -0.14658388495445251, 0.017057295888662338, 0.08829675614833832, -0.29078221321105957, -0.07065191864967346, 0.070744588971138, 0.036491766571998596, 0.26262158155441284, -0.10533158481121063, -0.07701831310987473, -0.050141941756010056, 0.15186017751693726, -0.04729876667261124, -0.0003843223676085472, -0.06602860987186432, 0.010624791495501995, 0.1079636663198471, 0.013911155052483082, 0.017956290394067764, -0.15206056833267212, 0.07157027721405029, -0.013916611671447754, 0.09343458712100983, 0.007073244079947472, -0.0410720631480217, -0.10685992240905762, -0.13833710551261902, 0.03516880050301552, 0.09257335960865021, -0.06351503729820251, 0.01972595974802971, 0.003343949094414711, 0.06845805048942566, 0.06264478713274002, 0.16131561994552612, 0.1737367957830429, 0.13311561942100525, 0.006057310849428177, 0.03512405604124069, 0.0852726399898529, 0.07161034643650055, -0.07476145029067993, -0.0673270970582962, 0.08036934584379196, 0.007141508162021637, 0.12135931849479675, 0.026889614760875702, 0.05471706762909889, 0.11799031496047974, 0.0953158289194107, 0.010830491781234741, -0.024030478671193123, -0.004471123218536377, -0.004950959235429764, -0.16629493236541748, -0.015243186615407467, 0.16700103878974915, -0.06255821883678436, 0.05506780371069908, 0.012102939188480377, -0.020448017865419388, -0.14690330624580383, -0.060438454151153564, -0.11965662240982056, 0.048639606684446335, 0.04902585223317146, 0.11758467555046082, -0.05570593848824501, -0.054317742586135864, -0.036417603492736816, 0.1098850816488266, 0.014032810926437378, -0.149993896484375, 0.2722824811935425, -0.13232824206352234, -0.03996708616614342, 0.2936195135116577, 0.0780336856842041, 0.11384129524230957, 0.11801999807357788, -0.03388771787285805, -0.0657326728105545, 0.02640788070857525, 0.061724260449409485, -0.1640893816947937, 1.342169311130112e-32, -0.0006770472973585129, 0.002166120335459709, 0.06754831224679947, 0.07462847232818604, 0.0008589187636971474, -0.08431115001440048, 0.08278262615203857, -0.06544885039329529, -0.21187421679496765, -0.12457658350467682, -0.13625675439834595, 0.14427490532398224, 0.0019262917339801788, 0.08352038264274597, -0.11454428732395172, -0.201777845621109, -0.051231686025857925, 0.06510447710752487, 0.046420782804489136, -0.08908069133758545, 0.07160250842571259, 0.03526323661208153, -0.0461142435669899, -0.00979267992079258, -0.015237868763506413, 0.11716832220554352, -0.0003718379884958267, 0.07725030928850174, 0.1240711510181427, 0.04010440409183502, -0.1882752776145935, 0.11445830762386322, 0.03732595220208168, -0.12225361168384552, 0.01759853959083557, -0.17031514644622803, -0.06571777164936066, -0.11424827575683594, -0.02216292917728424, 0.02266664430499077, 0.06966471672058105, 0.09111469984054565, -0.1073414608836174, -0.10812793672084808, 0.027032088488340378, -0.09025828540325165, -0.12816466391086578, 0.033599112182855606, 0.051272615790367126, -0.000929463654756546, 0.04122145101428032, 0.007602858357131481, -0.009138915687799454, 0.024236340075731277, -0.025408335030078888, 0.03432365506887436, -0.1886267364025116, -0.0601254478096962, 0.11731235682964325, 0.09947966039180756, -0.018653225153684616, 0.11757601797580719, -0.008493827655911446, 0.007662779185920954, -0.17736105620861053, 0.01806173473596573, 0.012850485742092133, 0.018196210265159607, -0.14253784716129303, 0.052620742470026016, 0.05564884841442108, 0.01609237678349018, 0.15607285499572754, 0.049045272171497345, 0.13508205115795135, -0.13158130645751953, 0.11332137882709503, 0.06952489167451859, -0.043278664350509644, 0.07518887519836426, -0.002743789926171303, 0.06748714298009872, -0.10183712840080261, 0.12291290611028671, 0.025126121938228607, -0.12827886641025543, -0.05016240477561951, -0.03611758351325989, -0.20270612835884094, -0.0585470013320446, 0.056351035833358765, -0.07615809142589569, -0.06317208707332611, 0.12523865699768066, 0.0670395940542221, -1.427392504627934e-32, 0.024977080523967743, -0.05518128722906113, 0.0547981858253479, -0.015637170523405075, -0.027522321790456772, 0.11732815206050873, 0.015915540978312492, -0.14983192086219788, 0.13788938522338867, -0.014247816056013107, 0.019697178155183792, 0.13999682664871216, -0.002381201833486557, -0.08878181129693985, -0.029830317944288254, -0.026558639481663704, 0.07567112892866135, -0.13985097408294678, -0.15251880884170532, -0.02087695524096489, 0.030981339514255524, 0.14346717298030853, -0.056331634521484375, 0.10519301891326904, -0.07988711446523666, 0.05833999812602997, 0.13052569329738617, 0.10295415669679642, 0.08208925276994705, -0.006542310584336519, -0.12044155597686768, 0.0009227361297234893, -0.26500654220581055, 0.053375840187072754, -0.02057831548154354, 0.014590047299861908, 0.07006677240133286, -0.1777820587158203, 0.015615269541740417, -0.11128637194633484, 0.06985259056091309, -0.038845568895339966, -0.09113731980323792, 0.026773419231176376, 0.0485689640045166, 0.027818236500024796, 0.09731864929199219, 0.007947640493512154, 0.11821885406970978, 0.0675562173128128, -0.020236235111951828, 0.08683755993843079, -0.07427255064249039, -0.07406832277774811, -0.058412835001945496, 0.0368824228644371, 0.0802767425775528, -0.09983253479003906, 0.02102721482515335, 0.0305920522660017, -0.024151774123311043, 0.1045013964176178, 0.12911784648895264, -0.07230605185031891, 0.022951964288949966, 0.16025538742542267, 0.07858985662460327, -0.08579210937023163, 0.08104215562343597, -0.03292505443096161, -0.034623049199581146, 0.0017238166183233261, -0.05222097411751747, -0.06606767326593399, 0.008500836789608002, 0.249854177236557, 0.0915236547589302, -0.22826817631721497, -0.06760852783918381, -0.002309893723577261, 0.035458702594041824, -0.030717963352799416, 0.053893595933914185, 0.014893281273543835, 0.12589454650878906, 0.006571041885763407, -0.07124214619398117, -0.0865839347243309, -0.05064821243286133, 0.048414383083581924, -0.09207935631275177, -0.15572768449783325, -0.0022355662658810616, 0.11361058801412582, -0.056341640651226044, -1.006308139039902e-07, 0.07662846148014069, -0.001827234635129571, -0.046575695276260376, -0.10069505870342255, 0.00985083170235157, -0.0542851947247982, -0.022820433601737022, -0.010099045932292938, -0.043463557958602905, 0.08151522278785706, 0.01209474727511406, 0.09973267465829849, -0.10962586104869843, -0.009098637849092484, -0.04243569076061249, 0.02510354295372963, 0.06569726020097733, 0.01126131322234869, -0.06470030546188354, -0.10304896533489227, -0.17443719506263733, 0.0345243439078331, 0.0345454104244709, -0.06133869290351868, 0.03741703927516937, -0.17998209595680237, -0.008552934043109417, 0.15522556006908417, 0.07694029062986374, -0.0033172834664583206, 0.008563684299588203, 0.0019565653055906296, 0.006346774287521839, 0.04289507865905762, -0.02552523836493492, -0.18762706220149994, -0.04180564358830452, 0.15641659498214722, -0.005047017242759466, 0.1329428106546402, 0.09179871529340744, 0.0067056952975690365, -0.06883250921964645, -0.07275328040122986, -0.12448135018348694, -0.06692584604024887, -0.1721959114074707, 0.00841684453189373, 0.025925081223249435, -0.06696934252977371, 0.024865062907338142, -0.04872140288352966, -0.04980940371751785, 0.01448990311473608, 0.048079319298267365, 0.18439710140228271, -0.016206208616495132, -0.10920891165733337, 0.10641786456108093, -0.056790515780448914, 0.02691146358847618, -0.16915352642536163, 0.06417158991098404, 0.0542907789349556], "changes": {"1wk": -14.116333927498737, "1mo": -10.87248440134472}}, {"text": "LIVE The latest news and updates on Trump's tariffs PREMIUM Bicara Therapeutics' Q3 Loss Narrows MT Newswires Tue, Nov 12, 2024, 5:06 PM In This Article: BCAX Bicara Therapeutics' Q3 Loss Narrows PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BCAX", "date": "2024-11-12T17:06:38", "sentiment": {"score": 0.017504042014479637, "confidence": 0.036619678139686584, "probabilities": {"positive": 0.036619678139686584, "negative": 0.019115636125206947, "neutral": 0.9442647099494934}}, "embedding": [-0.08465217053890228, 0.025738999247550964, 0.07976604998111725, 0.016636017709970474, 0.057762011885643005, 0.05114773288369179, 0.0027396706864237785, 0.09789443016052246, -0.009643960744142532, -0.004286576993763447, -0.03704207390546799, 0.15670984983444214, 0.042608484625816345, 0.02572137489914894, 0.0652693435549736, 0.11538978666067123, 0.13255617022514343, 0.08258675783872604, -0.18826469779014587, 0.07525018602609634, -0.040334951132535934, -0.045608844608068466, 0.05886489897966385, 0.1746235489845276, 0.003997881896793842, 0.05077129974961281, -0.031230801716446877, -0.07364992797374725, -0.04390433058142662, -0.04042598232626915, -0.10529425740242004, 0.0530090406537056, 0.06473782658576965, -0.20472200214862823, 0.029689881950616837, -0.17499519884586334, -0.08706824481487274, -0.051533374935388565, -0.0028055962175130844, 0.015538840554654598, 0.11905213445425034, -0.06200803443789482, -0.1968599110841751, 0.020907152444124222, -0.04244283586740494, -0.17651544511318207, -0.1406899094581604, 0.05108774080872536, 0.09570743143558502, 0.12213852256536484, -0.1009567379951477, -0.07234002649784088, 0.05391932278871536, 0.0465412475168705, -0.0542609803378582, -0.17989790439605713, -0.15392175316810608, 0.0025260511320084333, 0.06216628849506378, 0.06559914350509644, 0.0691288560628891, -0.07624071091413498, -0.04594988003373146, 0.06094703823328018, 0.10613346099853516, 0.022303402423858643, -0.10605425387620926, -0.036113422363996506, -0.07677987962961197, -0.08289401978254318, -0.04171460494399071, 0.007986004464328289, 0.023211456835269928, 0.02034066990017891, 0.12262006103992462, 0.07804809510707855, 0.2787116765975952, 0.014431613497436047, -0.05336214601993561, -0.08442802727222443, -0.07975181937217712, -0.09168528765439987, -0.07262224704027176, -0.0053808181546628475, 0.0637524202466011, -0.08665365725755692, -0.09500721096992493, -0.08824148774147034, -0.07363520562648773, -0.09984607249498367, 0.05056824907660484, -0.04377847909927368, 0.06876160204410553, 0.014348231256008148, -0.0988381952047348, -0.0123303746804595, -0.07820706814527512, -0.05632875859737396, -0.015888702124357224, 0.05219004303216934, 0.14947697520256042, -0.006516650319099426, -0.06571217626333237, -0.05143549665808678, -0.05695414915680885, -0.054276783019304276, -0.08146790415048599, 0.2231166809797287, 0.08348590135574341, 0.09667860716581345, 0.038035161793231964, 0.020399492233991623, 0.16282044351100922, -0.13488887250423431, -0.20872747898101807, 0.2762297987937927, -0.13554023206233978, -0.051606446504592896, 0.14846426248550415, 0.08928845077753067, 0.05347280576825142, 0.07987191528081894, -0.10003992915153503, -0.1096852570772171, -0.057467129081487656, -0.040747661143541336, 0.0040359655395150185, 1.2823964519483557e-32, -0.0619993731379509, 0.03151742368936539, 0.053073812276124954, 0.04283912852406502, 0.013083448633551598, 0.0301513671875, -0.04275968298316002, -0.2632664442062378, -0.10317834466695786, -0.1362818479537964, -0.11384134739637375, 0.335735946893692, -0.029142634943127632, 0.09698588401079178, -0.20360666513442993, -0.20813630521297455, -0.16613714396953583, 0.050845589488744736, 0.2001025378704071, 0.011146592907607555, 0.1912938952445984, -0.161002516746521, -0.0025343855377286673, 0.011459494940936565, 0.041625041514635086, 0.15417909622192383, 0.19212374091148376, -0.005296291783452034, 0.026278505101799965, 0.10137191414833069, -0.1556023508310318, 0.1426743119955063, -0.035365987569093704, -0.16455909609794617, 0.002948977518826723, 0.10979656875133514, -0.05807887762784958, -0.04144056886434555, -0.2213471382856369, -0.05627591535449028, -0.0027271374128758907, 0.028330180794000626, -0.08167899399995804, 0.03984369337558746, 0.0637529119849205, -0.06480024009943008, 0.054469697177410126, -0.04153238609433174, 0.11468352377414703, -0.09926097840070724, -0.028615610674023628, 0.07420318573713303, -0.1268414855003357, -0.05808476731181145, -0.017602575942873955, -0.033723749220371246, -0.038453251123428345, -0.1195187121629715, 0.11706626415252686, -0.059244535863399506, 0.2017892450094223, 0.1046806201338768, -0.004299193155020475, 0.03181683272123337, -0.221300408244133, 0.04825899004936218, -0.14163771271705627, -0.05183333158493042, -0.27017274498939514, 0.10367817431688309, 0.12938064336776733, 0.03446847200393677, 0.0507301390171051, 0.1275302618741989, -0.021364497020840645, 0.018281299620866776, -0.1274431347846985, 0.0754493996500969, 0.18622642755508423, -0.08709990978240967, 0.02059311978518963, -0.03784634917974472, 0.2103632539510727, 0.07203618437051773, 0.036737505346536636, -0.0749441459774971, -0.031111344695091248, -0.14736314117908478, -0.048981718719005585, 0.043553899973630905, -0.10397635400295258, 0.040246207267045975, -0.060403887182474136, 0.1850070208311081, -0.0335683673620224, -1.51517298608597e-32, -0.20679602026939392, 0.012166260741651058, 0.1378745287656784, -0.04948459565639496, -0.0745166689157486, -0.07637917250394821, -0.07254847139120102, 0.161165252327919, 0.2049800306558609, 0.061253149062395096, 0.036470815539360046, 0.07340184599161148, -0.08140166848897934, 0.2097843885421753, 0.02701122872531414, 0.0032488449942320585, 0.21778108179569244, -0.14344313740730286, -0.23657460510730743, -0.05668751522898674, -0.0017249193042516708, 0.17870831489562988, -0.2573295831680298, 0.2306942492723465, -0.04082939028739929, -0.016437500715255737, 0.13041822612285614, 0.0697622150182724, 0.06169562786817551, -0.10220178216695786, -0.16144858300685883, -0.1066717654466629, -0.23149284720420837, 0.12369705736637115, -0.05313354730606079, 0.055361226201057434, 0.1851501613855362, 0.00016282715660054237, -0.06276165693998337, -0.0928015485405922, 0.11798308044672012, -0.11464514583349228, -0.10006089508533478, 0.06513340771198273, 0.08192180097103119, 0.029371164739131927, -0.03133595734834671, -0.02211044915020466, 0.10032918304204941, 0.16302275657653809, 0.009751681238412857, 0.05945449694991112, 0.0027544787153601646, 0.11120903491973877, -0.1083202064037323, 0.053095437586307526, 0.05458971485495567, -0.025729892775416374, 0.07787487655878067, -0.014769558794796467, -0.00519636319950223, 0.18496230244636536, -0.02139424905180931, -0.08209194988012314, 0.01662280037999153, 0.02914765104651451, 0.09561842679977417, -0.04717083275318146, 0.17811289429664612, -0.0449693500995636, 0.06547126919031143, -0.04864665865898132, -0.13117490708827972, -0.2397470772266388, 0.06745009869337082, 0.22724583745002747, -0.10891802608966827, 0.08015602082014084, -0.04997707158327103, 0.031135570257902145, 0.22191667556762695, -0.18056005239486694, 0.14820334315299988, 0.07848706096410751, 0.05560583248734474, 0.08086073398590088, 0.08183317631483078, -0.08547154068946838, -0.09875362366437912, 0.006887928582727909, -0.18835237622261047, -0.20288702845573425, -0.2239999920129776, 0.08143284171819687, -0.008870862424373627, -9.975086356917018e-08, 0.07893472164869308, 0.01778257265686989, -0.14252270758152008, 0.10354077070951462, -0.03352281078696251, 0.0025865419302135706, -0.11971664428710938, -0.0005835601477883756, -0.08182135969400406, 0.21522867679595947, 0.033662475645542145, 0.029875313863158226, -0.13258662819862366, 0.0487956628203392, -0.03320113942027092, 0.036832310259342194, 0.09736800938844681, 0.09432036429643631, 0.043046049773693085, -0.14598515629768372, -0.0701598972082138, 0.14579688012599945, 0.17422805726528168, -0.09616483002901077, 0.05384380370378494, -0.06398225575685501, -0.03622353821992874, 0.06622563302516937, 0.15309078991413116, -0.04763765260577202, -0.07929492741823196, 0.017823461443185806, -0.154061421751976, -0.08671251684427261, -0.0462416410446167, -0.07483033090829849, -0.04987701028585434, 0.09663768857717514, 0.0721205547451973, 0.04347839578986168, 0.0430801585316658, -0.05409944802522659, 0.03844460844993591, 0.003302351338788867, -0.03415536507964134, -0.03864360600709915, -0.21062202751636505, -0.07050041854381561, 0.08307740092277527, -0.07222240418195724, -0.01528125163167715, -0.32450854778289795, 0.1915472447872162, -0.016539083793759346, 0.13903456926345825, 0.027500463649630547, 0.017666170373558998, -0.1264697015285492, -0.07288415729999542, -0.001167371403425932, 0.17722022533416748, -0.1565917432308197, 0.09155602753162384, 0.13773858547210693], "changes": {"1wk": -14.116333927498737, "1mo": -10.87248440134472}}]